Multicenter Phase II Study of Panitumumab and Irinotecan with or without Fluoropyrimidines in patients with KRAS Wild-type Metastatic Colorectal Cancer (PACIFIC)
Ontology highlight
ABSTRACT: Interventions: Irinotecan 150 mg/m2/biweekly div l-LV 200mg/m2/biweekly div 5-FU/bolus 400mg/m2/biweekly div (bolus) 5-FU/infusional 2,400mg/m2/biweekly div Panitumumab 6mg/kg/biweekly div or S-1 80mg/m2/day p.o. day 1-7 Irinotecan 150mg/m2 day 1 Panitumumab 6mg/kg/biweekly div
Irinotecan 150mg/m2/ biweekly div Panitumumab 6mg/kg/biweekly div
Primary outcome(s): Progression-free survival
Study Design: Parallel Randomized
DISEASE(S): Colorectal Cancer
PROVIDER: 2623074 | ecrin-mdr-crc |
REPOSITORIES: ECRIN MDR
ACCESS DATA